In this study we established a UK-wide multicentre collaboration to recruit a large cohort of patients treated with anti-TNF agents and tested the hypothesis that confirmed RA susceptibility factors, namely RF, anti-CCP, SE and PTPN22 620W, are associated with clinical response in patients treated with anti-TNF. Here, PTPN22 is linked to rheumatoid arthritis.